SCHEMBL3479532

SCHEMBL3479532

CN1CCN(c2ccccc2Cl)c2ccc(C(F)(F)F)cc2C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.45
MAT2A P31153 1/20 0.41
FPR2 P25090 3/20 0.40
ALDH1A1 P00352 2/20 0.40
LMNA P02545 2/20 0.40
TP53 P04637 2/20 0.40
CYP3A4 P08684 2/20 0.40
MAPT P10636 2/20 0.40
MAPK1 P28482 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
GHSR Q92847 2/20 0.40
DRD2 P14416 2/20 0.40
DRD3 P35462 2/20 0.40
HRH1 P35367 2/20 0.40
NPC1 O15118 1/20 0.40
MLNR O43193 1/20 0.40
USP1 O94782 1/20 0.40
ESR1 P03372 1/20 0.40
CYP1A2 P05177 1/20 0.40
ABCB1 P08183 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3479706 0.86 SCN9A (0.45) SCN9AFPR2ALDH1A1LMNATP53
SCHEMBL3222283 0.83 SCN9A (0.54) SCN9AFPR2ALDH1A1LMNATP53
SCHEMBL3232308 0.83 P2RX7 (0.46) ALDH1A1MAPTDRD2DRD3SLC6A2
SCHEMBL3479531 0.83 SCN9A (0.48) SCN9AFPR2ALDH1A1LMNATP53
SCHEMBL3233898 0.82 ALDH1A1 (0.42) ALDH1A1DRD2DRD3DRD1SLC6A2
SCHEMBL3228501 0.81 SCN9A (0.53) SCN9ASLC6A4KCNH2HRH4POLB
SCHEMBL3233624 0.81 DRD2 (0.47) LMNAMAPTDRD2DRD3HRH1
SCHEMBL3227422 0.81 SCN9A (0.52) SCN9AALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL3221248 0.79 DRD1 (0.51) DRD2DRD3DRD1SLC6A2SLC6A4
SCHEMBL3479780 0.79 SCN9A (0.43) SCN9AALDH1A1LMNATP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D SCN9A 795/4885MAT2A 3137/4885FPR2 730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.